Hydroxychloroquine Dosing in Systemic Sclerosis
There is no established evidence-based dosing regimen for hydroxychloroquine in systemic sclerosis, as it is not a recommended treatment for this condition.
Current Evidence and Guidelines
The most recent and authoritative EULAR 2025 guidelines for systemic sclerosis management 1 do not include hydroxychloroquine in any of their 22 recommendations across all SSc manifestations (Raynaud's phenomenon, digital ulcers, pulmonary arterial hypertension, scleroderma renal crisis, skin fibrosis, interstitial lung disease, gastrointestinal, or musculoskeletal involvement). This represents a comprehensive, updated consensus from systemic sclerosis experts.
Why HCQ is Not Recommended for SSc
The evidence shows hydroxychloroquine does not improve functional outcomes in systemic sclerosis:
A 2025 EUSTAR cohort analysis 2 of 468 SSc patients using HCQ (matched 3:1 with controls) found no significant improvement in:
- Health Assessment Questionnaire Disability Index (HAQ-DI)
- Cochin Hand Function Status (CHFS)
- These findings held over 365 days of follow-up
Only 2.6% of SSc patients in the large EUSTAR registry used HCQ, reflecting its limited role 2
Limited Historical Context
A 2012 expert consensus survey 3 mentioned hydroxychloroquine only for SSc-related inflammatory arthritis as a potential add-on therapy (31% of experts), but this was:
- Not first-line (methotrexate was preferred at 60%)
- Had only 62% agreement among experts
- Predates current evidence showing lack of efficacy
Emerging Mortality Data (Requires Caution)
A 2026 retrospective study 4 showed lower mortality (RR 0.719) but higher pulmonary hypertension rates (RR 1.124) in HCQ users. However, this observational data cannot establish causation and may reflect selection bias.
If HCQ Were to Be Used (Off-Label)
Should you decide to use HCQ off-label in SSc despite lack of evidence, apply dosing principles from established rheumatic diseases:
Dosing Parameters
- Maximum dose: <5 mg/kg real body weight per day 5, 6, 7
- Typical range: 200-400 mg daily (or divided twice daily) 5
- Use real body weight, not ideal body weight for calculation 6
Critical Safety Monitoring
Retinal screening:
Dose reduction by 25% if eGFR <30 mL/min/1.73m² 7
Screen for G6PD deficiency before initiation, especially in men of African, Asian, or Middle Eastern descent 7
Common Pitfalls
- Do not use ideal body weight - this leads to overdosing in thin patients 6
- Do not assume efficacy - the drug has proven benefits in SLE and RA but not in SSc 2
- Renal disease increases drug levels unpredictably; adjust dosing and monitoring 6
Recommended Approach for SSc
Instead of hydroxychloroquine, follow evidence-based EULAR 2025 recommendations 1:
- Skin fibrosis: Methotrexate, mycophenolate mofetil, or rituximab
- Interstitial lung disease: MMF, cyclophosphamide, rituximab, or nintedanib
- Musculoskeletal involvement: Methotrexate
- Raynaud's/digital ulcers: Calcium channel blockers, PDE5 inhibitors, or iloprost
The absence of HCQ from current SSc guidelines, combined with negative functional outcome data 2, makes it an inappropriate choice for SSc-specific manifestations.